BMS and Samsung announced today that they are extending their manufacturing agreement to make more biologics, and as BMS says to secure manufacturing capacity for its new drugs for next 10 years. The deal follows the most recent cut between the two companies, where Samsung is making BMS' Yervoy melanoma fighting drug.
For its part, Samsung, a new player to the biotech field, has not allowed the grass to grow under its feet. The company is operating 30,000 L of bioreactor capacity now ( 6 x 5000L) and is rapidly adding 5x as much with a new plant addition that will house 10 x 15,000L (150,000 L) of new capacity. This second plant should be ready by Q1 2015. Plans are also on the board for 2000 L of clinical capacity in 2016. This is support phase I/II type clinical trials.
While BMS may be its primary client, Samsung also has a deal with Roche cut in October 2013, and is actively seeking further partners to utilize all of its new capacity. See BioPharma-reporter.
Posted by Bruce Lehr April 28th 2014